Rituximab biosimilar - Lonza/Teva Pharmaceutical Industries

Drug Profile

Rituximab biosimilar - Lonza/Teva Pharmaceutical Industries

Alternative Names: TL-011

Latest Information Update: 30 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teva Pharmaceutical Industries - Lonza (JV)
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 25 Jul 2013 Discontinued - Phase-I for Diffuse large B cell lymphoma (combination therapy, first-line therapy) in Hungary, Italy, Latvia, Poland, Russia, Spain, Ukraine, Estonia, Bulgaria and France (IV)
  • 25 Jul 2013 Discontinued - Phase-I/II for Rheumatoid arthritis in Italy and United Kingdom (IV)
  • 25 Jul 2013 Discontinued - Phase-III for Rheumatoid arthritis in Hungary, Poland, Spain, Czech Republic and Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top